Charles River Laboratories International (CRL)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.27 (+0.14%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Charles River Laboratories International (CRL)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Key Insights

Critical company metrics and information
  • Share Price

    $191.81
  • Market Cap

    $9.81 Billion
  • Total Outstanding Shares

    51.14 Million Shares
  • Total Employees

    21,400
  • Dividend

    No dividend
  • IPO Date

    June 23, 2000
  • SIC Description

    Services-commercial Physical & Biological Research
  • Homepage

    https://www.criver.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

September 29, 2023 to September 28, 2024
MetricValue
Net Cash Flow From Investing Activities$-407.35 Million
Net Cash Flow, Continuing$37.33 Million
Net Cash Flow$46.02 Million
Net Cash Flow From Operating Activities$796.16 Million
Net Cash Flow From Operating Activities, Continuing$796.16 Million
Net Cash Flow From Financing Activities, Continuing$-351.48 Million
Exchange Gains/Losses$8.70 Million
Net Cash Flow From Investing Activities, Continuing$-407.35 Million
Net Cash Flow From Financing Activities$-351.48 Million

Income Statement

September 29, 2023 to September 28, 2024
MetricValue
Net Income/Loss Attributable To Parent$423.78 Million
Preferred Stock Dividends And Other Adjustments$10.70 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$10.70 Million
Net Income/Loss Attributable To Noncontrolling Interest$4.21 Million
Basic Average Shares$102.92 Million
Income/Loss From Continuing Operations After Tax$427.99 Million
Benefits Costs and Expenses$3.55 Billion
Other Operating Expenses$2.76 Billion
Selling, General, and Administrative Expenses$752.44 Million
Costs And Expenses$3.57 Billion
Operating Income/Loss$527.96 Million
Revenues$4.06 Billion
Net Income/Loss Available To Common Stockholders, Basic$413.08 Million
Diluted Average Shares$155.23 Million
Basic Earnings Per Share$8.05
Income/Loss From Continuing Operations Before Tax$512.79 Million
Operating Expenses$3.51 Billion
Net Income/Loss$427.99 Million
Diluted Earnings Per Share$8.01
Income Tax Expense/Benefit$90.62 Million

Balance Sheet

September 29, 2023 to September 28, 2024
MetricValue
Noncurrent Liabilities$3.16 Billion
Inventory$336.20 Million
Other Current Assets$1.07 Billion
Assets$8.00 Billion
Redeemable Noncontrolling Interest$40.59 Million
Liabilities And Equity$8.00 Billion
Current Assets$1.49 Billion
Current Liabilities$1.01 Billion
Temporary Equity$40.59 Million
Noncurrent Assets$6.51 Billion
Accounts Payable$135.96 Million
Prepaid Expenses$92.63 Million
Equity$3.79 Billion
Other Current Liabilities$665.18 Million
Wages$211.08 Million
Equity Attributable To Noncontrolling Interest$4.85 Million
Liabilities$4.18 Billion
Equity Attributable To Parent$3.78 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Charles River Laboratories International (CRL)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.